Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?

World Journal of Surgery

Volumn 34, Issue 7, 2010, Pages 1434-1441

  Falck, Anna Karin ^a   Fernö, Mårten ^a   Bendahl, Pär Ola ^a   Rydén, Lisa ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HER2 PROTEIN, HUMAN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CYTOLOGY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955472477     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-010-0499-z     Document Type: Article

References (19)

1. S Cinieri L Orlando P Fedele, et al. 2007 Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007. St. Gallen international expert consensus conference Ann Oncol 18 Suppl 6 vi63 vi65 10.1093/annonc/mdm227 17591835
2. CL Carter C Allen DE Henson 1989 Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases Cancer 63 181 187 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H 1:STN:280:DyaL1M%2FovFCqug%3D%3D 2910416 (Pubitemid 19032001)
3. I Jatoi SG Hilsenbeck GM Clark, et al. 1999 Significance of axillary lymph node metastasis in primary breast cancer J Clin Oncol 17 2334 2340 1:STN:280:DC%2BD3c%2FjtVShtg%3D%3D 10561295
4. Early Breast Cancer Trialists Group 1998 Tamoxifen for early breast cancer: an overview of the randomized trials Lancet 351 1451 1467 10.1016/S0140-6736(97)11423-4 (Pubitemid 28227036)
5. MJ Piccart-Gebhart M Procter B Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L 16236737 (Pubitemid 41464705)
6. Breast International Group (BIG) 1-98 Collaborative Group B Thurlimann, et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757 10.1056/NEJMoa052258 16382061 (Pubitemid 43016814)
7. SA Hurvitz RJ Pietras 2008 Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions Cancer 113 2385 2397 10.1002/cncr.23875 1:CAS:528:DC%2BD1cXhtlKru77P 18819158
8. CA Klein 2009 Parallel progression of primary tumors and metastases Nat Rev Cancer 9 4 302 312 10.1038/nrc2627 1:CAS:528:DC%2BD1MXjsFSrsr8%3D 19308069
9. JR De la Haba-Rodriguez M Ruiz Borrego A Gómez España, et al. 2004 Comparative study of the immunohistochemical phenotype in breast cancer and its lymph node metastatic location Cancer Investig 22 2 219 224 10.1081/CNV-120030210 (Pubitemid 38725176)
10. E Dikicioglu S Barutca N Meydan, et al. 2005 Biological characteristics of breast cancer at the primary tumor and the involved lymph nodes Int J Clin Pract 59 9 1039 1044 10.1111/j.1742-1241.2005.00546.x 1:STN:280: DC%2BD2MvkvFSjsw%3D%3D 16115179
11. F Cardoso A Di Leo D Larsimont, et al. 2001 Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat-shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes Ann Oncol 42 7 615 620 10.1023/A:1011182524684 (Pubitemid 32519912)
12. G Chebil PO Bendahl I Idvall, et al. 2003 Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer-clinical associations and reasons for discrepancies Acta Oncol 42 719 725 10.1080/02841860310004724 1:CAS:528:DC%2BD3sXpvFyrs7c%3D 14690157 (Pubitemid 37445291)
13. G Honeth PO Bendahl M Ringner, et al. 2008 The CD44+/CD24- phenotype is enriched in basal-like breast tumors Breast Cancer Res 10 R53 10.1186/bcr2108 18559090
14. C Ahlin K Aaltonen RM Amini, et al. 2007 Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51 491 498 10.1111/j.1365-2559.2007.02798.x 1:STN:280: DC%2BD2srmtFWhug%3D%3D 17711446 (Pubitemid 47437828)
15. TE Becker RE Ellsworth B Deyarmin, et al. 2008 The genomic heritage of lymph node metastases: implications for clinical management of patients with breast cancer Ann Surg Oncol 15 1056 1063 10.1245/s10434-008-9815-3 18246400
16. B Weigelt AM Glas LF Wessels, et al. 2003 Gene expression profiles of primary breast tumors maintained in distant metastases Proc Natl Acad Sci U S A 100 15901 15905 10.1073/pnas.2634067100 1:CAS:528:DC%2BD2cXhtVCktg%3D%3D 14665696 (Pubitemid 38021087)
17. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 10869 10874 10.1073/pnas.191367098 1:CAS:528: DC%2BD3MXntVGmsbo%3D 11553815 (Pubitemid 32878711)
18. A Santinelli E Pisa E Stramazzotti, et al. 2008 HER2 status discrepancy between primary lesions and metastatic sites. Impact on targeted therapy Int J Cancer 122 5 999 1004 10.1002/ijc.23051 1:CAS:528:DC%2BD1cXhslGhtb0%3D 17973263 (Pubitemid 351213996)
19. L Ryden M Haglund PO Bendahl, et al. 2009 Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer-a national survey performed at pathology departments in Sweden Acta Oncol 48 860 866 19353340